TEVA PHARMACEUTICAL INDUSTRIES LTD - 8-K Filing

Teva announces departure of R&D Chief Dr. Eric Hughes and appoints David Gardiner as interim transition lead. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 7.01 Regulation FD Disclosure On November 18, 2026, Teva issued a press release announcing that Dr, 9.01 Financial Statements and Exhibits(d) Exhibits Exhibit Description of Document 99)

SEC EDGAR ·

Tickers: $TEVA

Read the full article at SEC EDGAR

Part of the story QXO, Inc. - 8-K Filing (52 articles)

More Regulatory news